CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 8 enrolled
Drug / intervention
Semaglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05788965
NCT05788965Phase 3Completed
CompareCT.gov

Efficacy and Safety of GLP-1 Agonist Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study

University of Minnesota·interventional·Posted Mar 29, 2023·Updated Jan 21, 2026

In Brief

A Phase 3 clinical trial evaluating Semaglutide for Cystic Fibrosis and Cystic Fibrosis-related Diabetes. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis, Cystic Fibrosis-related Diabetes
CountriesUnited States
CollaboratorsCystic Fibrosis Foundation

Timeline

Phase 3CompletedFinished
202420252026
First PostedMar 29, 2023
Enrollment StartOct 16, 2023
Primary CompletionDec 23, 2024
Study CompletionDec 31, 2024
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 3.3 years ago

Interventions

Semaglutidedrug

glucagon-like peptide 1 (GLP-1) receptor agonist